Imetelstat in patients with lower-risk MDS: Updates from the IMerge trial

In patients with lower-risk myelodysplastic neoplasms (LR-MDS) who are red blood cell (RBC) transfusion-dependent, there remains a need for novel therapies following relapsed or refractory disease or failure of erythropoiesis-stimulating agents.¹ Imetelstat is a first-in-class telomerase inhibitor, targeting the ribonucleic acid template of telomerase.¹ The MDS Hub has previously reported on the efficacy of imetelstat in patients with highly transfusion-dependent MDS and LR‑MDS from the phase II portion of the IMerge trial (NCT02598661).

We are pleased to provide a summary of three oral presentations from the European Hematology Association (EHA) 2023 Hybrid Congress, relating to the phase III results from the IMerge trial; Uwe Platzbecker¹ presented efficacy and safety data, Valeria Santini² covered disease activity, and Chapuis³ discussed biological pathways underlying the clinical response to imetelstat. These findings were also outlined by Zeidan⁴ at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting.

IMerge study design and patient baseline characteristics

Patients with LR-MDS were randomized to receive imetelstat or placebo (Figure 1).^1,2,4

Ten patients were included in the subgroup analysis to identify biological pathways associated with clinical response of imetelstat, six of whom were transfusion independent (TI) responders and four were TI non-responders.³ Bone marrow (BM), mononuclear cell transcriptome, peripheral blood immune cell landscape, and plasma cytokines were analyzed.³

At the data cut-off date of October 13, 2022, 178 patients with LR-MDS were included, who were heavily transfusion dependent in both the imetelstat and placebo groups.^1,2,4 Baseline characteristics are shown in Table 1.

Table 1. Baseline characteristics*

Imetelstat increased RBC-TI up to 52 weeks^1,4

At a median follow-up of 18 months, 77.1% vs 76.3% of patients in the imetelstat and placebo group, respectively, discontinued treatment due to lack of efficacy (23.8% vs 42.4%), adverse events (AEs) (16.1% vs 0%), and loss of response (14.4% vs 1.7%).

RBC-TI was consistently higher with imetelstat compared with placebo at 8, 16, 24, and 52 weeks (Figure 2).

• The median duration of RBC-TI was 51.6 weeks vs 13.3 weeks in the imetelstat and placebo groups, respectively (hazard ratio [HR], 0.23; p < 0.001).
• 8-week RBC-TI rate was also greater with imetelstat versus placebo across subgroups, including those with ring sideroblasts (RS) and those transfused with >6 units/8 weeks.
• The 24-week RBC-TI seen with imetelstat was irrespective of baseline mutation status (p < 0.001), baseline telomerase activity (p = 0.074), telomerase length (0.001), and human telomerase reverse transcriptase (p = 0.042).

In addition, patients treated with imetelstat demonstrated:

• An overall durability of RBC-TI across all subgroups at 8 weeks (HR, 0.23; p < 0.001) and 24 weeks (p < 0.001).
• A greater reduction in mean RBC transfusion units over time compared with placebo (p = 0.042).
• Greater hematologic improvement-erythroid rates versus placebo (50% vs 8%, p < 0.001). This was also noted for major (30.9% vs 0%, p < 0.001) and minor (44.3% vs 9.5%, p < 0.001) hematologic improvement-erythroid rates.

The most common safety signals were hematologic^1,4

• The most frequently reported Grade 3–4 AEs were thrombocytopenia (62%) and neutropenia (68%) in the imetelstat group, and thrombocytopenia (8%) and anemia (7%) in the placebo group; Grade 3 febrile neutropenia was observed in one patient in the imetelstat group.
  • The median duration of thrombocytopenia was 1.4 weeks (range, 0.1–12.6 weeks) and 2 weeks (range, 0.3–11.6 weeks) in the imetelstat and placebo groups, respectively.
  • The median duration of neutropenia was 1.9 weeks (range, 0.0–15.9 weeks) and 2.2 weeks (range, 1.0–4.6 weeks) in the imetelstat and placebo groups, respectively.
  • Both thrombocytopenia and neutropenia were resolved in >80% of patients in the imetelstat group within 4 weeks.
• No fatal hematologic AEs were observed in either treatment group.
• Fewer than 15% of patients discontinued treatment due to treatment-emergent AEs; however, the median time to treatment discontinuation was 21.1 weeks (range, 2.3–44 weeks).

Imetelstat induces cytogenetic response and increases TI duration^2,4

Cytogenetic complete or partial response was achieved by 35% (imetelstat) and 15% (placebo) of patients with cytogenetic abnormalities at baseline, and 8-week RBC-TI was attained by 89% (imetelstat) and 50% (placebo) of patients with a cytogenetic response.

Compared with placebo, patients treated with imetelstat showed:

• ≥50% reduction in central BM RS (40.8% vs 9.7%); interestingly, patients in the imetelstat group achieving ≥50% reduction in central BM RS also showed a higher rate of RBC-TI.
• A greater reduction in variant allele frequency (VAF) of SF3B1 (p <0.001), TET2 (p = 0.032), DNMT3A (p = 0.019), and ASXL1 (p = 0.146) genes.
• A higher proportion with ≥50% VAF reduction in SF3B1 (29.5% vs 2.6%, p = 0.001), TET2 (34.3% vs 8.3%), DNMT3A (11.1% vs 0%), and ASXL1 (40% vs 16.7%); the reduction in SF3B1 VAF was maintained over time in the imetelstat group.

In those patients who received imetelstat, the reductions noted in VAF in SF3B1, TET2 and DNMT3A genes correlated with clinical outcomes:

• Longer duration of RBC-TI: SF3B1 (p < 0.001), TET2 (p < 0.001), and DNMT3A (p = 0.019)
• Increased hemoglobin levels: SF3B1 (p < 0.001), TET2 (p < 0.001), and DNMT3A (p = 0.013)

In the imetelstat group, RBC-TI also correlated with reductions in RS-positive cells, cytogenetic responses, and VAF in commonly mutated genes at 8 weeks and 24 weeks (Figure 3).

• Those who attained ≥50% reduction in SF3B1 had a higher 1-year RBC-TI compared with those in      the placebo group (47.8% vs 5.5%, p < 0.001).
• Similarly, patients who attained ≥50% reduction in TET2 had a higher 1-year RBC-TI compared with those in the placebo group (50% vs 8.7%, p = 0.011).

Imetelstat modulates the immune landscape in LR-MDS³

Of the ten patients included, six patients had International Prognostic Scoring System (IPSS) LR-MDS and four had intermediate-1 MDS. A total of 1,185 differentially expressed genes were identified; 1,150 were downregulated and 35 were upregulated.

In patients who achieved TI:

• A higher number of differentially expressed genes were expressed in patients achieving TI versus those who did not achieve TI (p = 0.05).

• Innate and adaptive immune responses were suppressed and pro-inflammatory interleukin (IL)-8 or CXCL9 chemokine levels were lower.
• Treatment with imetelstat for 4–7 months resulted in:
  • Upregulation of pathways involved in T-cell activation and B-cell proliferation and downregulation of IL-6 and IL-1β production.
  • Reduced proportion of human leukocyte antigen-DR monocytes and increased pro-inflammatory monocyte CD16⁺ levels.
  • Increased levels of CD8⁺ terminal effector T cells and B cells
  • Increased levels of tumor necrosis factor α, CXCL9, IL-17F, and IL-6, but decreased S100A8/A9 heterodimer (after two cycles of treatment).

Conclusion

These findings demonstrate the clinically meaningful efficacy of imetelstat in patients with heavily transfusion-dependent LR-MDS. Patients treated with imetelstat achieved higher cytogenetic response rates and consequently 8-week RBC TI. The safety profile of imetelstat was also consistent with previous studies.¹ There was a sustained reduction in SF3B1 VAF over time and greater reduction in multiple genes.^1,2 The findings suggest that imetelstat may impact the biology of LR-MDS and potentially lead to change in the course of the disease by reducing or removing malignant clones and improving inefficient erythropoiesis.² Imetelstat was associated with induction of an adaptive immune response, indicating that reconfiguration of immune cells may result in hematopoietic activity. Further studies are needed to establish the contribution of immunomodulation to the erythroid response.